Gravity Analytica

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

SRRK 11.01.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-12

Name of Upcoming Event:Investor Relations Conference Call

Full Press Release SEC Filings Our SRRK Tweets

About Gravity Analytica

Recent Filings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 1, 2024--Scholar Rock(NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2024 financial results and provide a business update onTuesday, November 12, 2024, at8:15am ET.

To access the live conference call, participants may registerhere. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of theScholar Rockwebsite athttp://investors.scholarrock.com. To participate via telephone, please register in advancehere. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. An archived replay of the webcast will be available on the Company’s website for approximately 90 days.

AboutScholar Rock

Scholar Rockis a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade,Scholar Rockhas created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.

This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies,Scholar Rockworks every day to create new possibilities for patients. Learn more about our approach atScholarRock.comand follow @ScholarRock and on LinkedIn.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company websitewww.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs,Securities and Exchange Commissionfilings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Scholar Rock^®is a registered trademark ofScholar Rock, Inc.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241101586315/en/

Scholar Rock:InvestorsRushmie NofsingerScholar Rockrnofsinger@scholarrock.com ir@scholarrock.com857-259-5573

MediaMolly MacLeodScholar Rockmmacleod@scholarrock.com media@scholarrock.com802-579-5995

Source:Scholar Rock

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com